<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04207385</url>
  </required_header>
  <id_info>
    <org_study_id>KY20192104-X-1</org_study_id>
    <nct_id>NCT04207385</nct_id>
  </id_info>
  <brief_title>Accurate Clinical Study of Medication in Patients With Depression Via Pharmacogenomics (PGx) and Therapeutic Drug Monitoring (TDM) of Venlafaxine</brief_title>
  <official_title>Accurate Clinical Study of Medication in Patients With Depression Via Pharmacogenomics (PGx) and Therapeutic Drug Monitoring (TDM) of Venlafaxine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Xijing Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Xijing Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the efficacy of PGx-guided medication in patients with depression&#xD;
      treated with Venlafaxine and the efficacy of the combination of PGx and TDM in patients with&#xD;
      depression treated with Venlafaxine. Half of participants will receive PGx-guided treatment,&#xD;
      while the other half will receive routine treatment. After the 8th week, the PGx-guided&#xD;
      treatment group would be randomly divided into two groups. Of which, half of participants&#xD;
      will receive the combination of PGx and TDM, and the other half will receive PGx -guided&#xD;
      medication only.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The current clinical medication is based on &quot;Trial and Error&quot;, while the traditional&#xD;
      medication is mainly based on experience. The study mainly optimizes the treatment path from&#xD;
      two perspectives: to help clinicians select drugs accurately through the detection of PGx; to&#xD;
      help clinicians monitor the whole process of drug use through TDM and adjust the dosage in&#xD;
      time to achieve better treatment.&#xD;
&#xD;
      PGx tests take the information of metabolic, transporting and target genetic factors into&#xD;
      account comprehensively. Furthermore, clinical effects depend on blood concentration rather&#xD;
      than dose concentration. TDM aims to monitor blood concentration, which is related to drug&#xD;
      efficacy and toxicity.&#xD;
&#xD;
      Venlafaxine is an antidepressant drugs of the 5-hydroxytryptamine selective seratonin&#xD;
      re-uptake inhibitors (SSRIs), which has been approved by FDA for the treatment of depressive&#xD;
      disorders, depressive disorders with anxiety symptoms, generalized anxiety disorders and&#xD;
      social anxiety disorders since 1994.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Anticipated">November 20, 2021</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Score reduction rate of Hamilton Depression Rating Scale</measure>
    <time_frame>3 days</time_frame>
    <description>Reduction Rate=[(total score before treatment-total score after treatment)/total score before treatment] *100%&#xD;
Healed: reduction rate ≥ 75%;&#xD;
Significant Effective: reduction rate≥50％and &lt;75％; ③Effective: reduction rate≥25％ and &lt;50％; ④Invalid: Reduction rate &lt; 25%</description>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>A group: Routine treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Routine dosage of venlafaxine during the first 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B group: PGx-guided group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The PGx test results guide the dosage of venlafaxine during the first 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C group: Routine PGx-guided group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The PGx test results guide the dosage of venlafaxine between 4th and 8th weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D group: The combination of PGx and TDM group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The PGx and TDM test results guide the dosage of venlafaxine between 4th and 8th weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>pharmacogenomics</intervention_name>
    <description>pharmacogenomics</description>
    <arm_group_label>B group: PGx-guided group</arm_group_label>
    <arm_group_label>C group: Routine PGx-guided group</arm_group_label>
    <arm_group_label>D group: The combination of PGx and TDM group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>pharmacogenomics &amp; therapeutic drug monitoring</intervention_name>
    <description>pharmacogenomics &amp; therapeutic drug monitoring</description>
    <arm_group_label>D group: The combination of PGx and TDM group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Venlafaxine</intervention_name>
    <description>Venlafaxine hydrochloride sustained-release capsules 75mg x 14 tablets x 1 case 75-225mg/morning</description>
    <arm_group_label>A group: Routine treatment group</arm_group_label>
    <arm_group_label>B group: PGx-guided group</arm_group_label>
    <arm_group_label>C group: Routine PGx-guided group</arm_group_label>
    <arm_group_label>D group: The combination of PGx and TDM group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients with endogenous depression, with any of the following 4 symptoms: ① Interest&#xD;
             Loss; ② Hypothymia; ③ Early awakening; ④ Serious in the morning and relieved at night;&#xD;
             ⑤ Hysteresis or agitation of movement of Spirit; ⑥ Appetite loss; ⑦ Weight loss; ⑧&#xD;
             Loss of libido;&#xD;
&#xD;
          -  Scores of 17 items in Hamilton Depression Scale (HAM-D17): over 17 points;&#xD;
&#xD;
          -  First-episode patients or relapsed patients without taking any antidepressant drugs in&#xD;
             the recent 3 months;&#xD;
&#xD;
          -  No significant abnormalities are shown in physical examination (temperature, pulse,&#xD;
             blood pressure, head and neck, chest and abdomen).&#xD;
&#xD;
          -  No obvious abnormalities in laboratory examination (Thyroid Function).&#xD;
&#xD;
          -  Informed patient consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Those diagnosed with mental disorders other than major depressive disorders (with the&#xD;
             exception of combination of anxiety disorders); non-endogenous depressive disorders;&#xD;
&#xD;
          -  Patients with stroke, brain tumor and other brain organic diseases;&#xD;
&#xD;
          -  Patients receiving combined drugs (but there is no need to exclude patients receving&#xD;
             drugs against sleep disorders, such as Eszopiclone, alprazolam or estazolam);&#xD;
&#xD;
          -  History of drug allergy;&#xD;
&#xD;
          -  Pregnant and lying-in women;&#xD;
&#xD;
          -  Patients with serious suicidal tendencies.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huaning Wang</last_name>
    <role>Study Chair</role>
    <affiliation>Deputy Chief Physician</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ping Zhou</last_name>
    <role>Principal Investigator</role>
    <affiliation>Attending Physician</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Yihuan Chen</last_name>
    <role>Principal Investigator</role>
    <affiliation>Attending Physician</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Huizhen Lu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Resident Physician</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Qinghong Yan</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nurse</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huaning Wang</last_name>
    <phone>+86 13609161341</phone>
    <email>xskzhu@fmmu.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Xijing Hospital</name>
      <address>
        <city>Xi'an</city>
        <state>Shanxi</state>
        <zip>710032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huaning Wang</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>December 18, 2019</study_first_submitted>
  <study_first_submitted_qc>December 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2019</study_first_posted>
  <last_update_submitted>December 19, 2019</last_update_submitted>
  <last_update_submitted_qc>December 19, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 20, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pharmacogenomics</keyword>
  <keyword>PGx</keyword>
  <keyword>therapeutic drug monitoring</keyword>
  <keyword>TDM</keyword>
  <keyword>Venlafaxine</keyword>
  <keyword>depression</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Venlafaxine Hydrochloride</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

